Skip to main content
Equibles
SGHT logo

SGHT · Sight Sciences, Inc. · Earnings Call Transcripts & Audio

Track SGHT — free

Use SGHT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SGHT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.36 +0.01 (+0.11%)
Russell 2000 member Rebalance outlook locked
Market Cap
$491.94M
Shares
55.09M
Volume · Sep 30 570.86K Avg daily vol (3M) 234.37K

Sight Sciences, Inc. Earnings Call Transcripts

Quarterly earnings calls for Sight Sciences, Inc. (SGHT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲42.6% $18.68M −$22.23M '22 Q3 22-11-10 ▲39.9% $20.54M −$16.91M '22 Q4 23-01-09 ▲26.5% $18.82M −$17.07M '23 Q1 23-05-04 ▲36.2% $23.47M −$14.75M '23 Q2 23-08-03 ▲7.1% $20.01M −$13.04M '23 Q3 23-11-07 ▼8.7% $18.75M −$10.69M '23 Q4 24-03-07 ▲2.3% $19.27M −$16.27M '24 Q1 24-03-31 ▼9% $21.37M −$12.33M '24 Q2 24-08-01 ▲0.7% $20.16M −$11.07M '24 Q3 24-11-07 ▲1.7% $19.07M −$11.85M '24 Q4 25-01-14 ▼9.1% $17.51M −$14.15M '25 Q1 25-05-08 ▼8.5% $19.56M −$11.94M '25 Q2 25-08-07 ▼1.2% $19.91M −$8.17M '25 Q3 25-11-06 ▲6.9% $20.39M −$4.16M '25 Q4 26-03-04 ▲12.5% $19.70M −$12.98M '26 Q1 26-05-06 LATEST ▲19.5% $23.39M −$4.45M '26 Q2 26-08-05
Conference
Investor event
2026-09-15
Sight Sciences, Inc. (SGHT) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
Confident tone Interventional Glaucoma / Omni platform Payer coverage and market access expansion Path to profitability / cash flow discipline
Revenue
$23.39M
▲ 19.5% YoY
Diluted EPS
$-0.08
Gross margin
91.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Confident tone Interventional Glaucoma (Omni) Growth Market Access Expansion (MACs and Commercial Payers) Intersection of Intervention (Cross-Selling Synergies)
Revenue
$19.70M
▲ 12.5% YoY
Diluted EPS
$-0.24
Gross margin
86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Positive tone 2026 financial guidance and growth outlook Interventional Dry Eye / TearCare commercialization MAC reimbursement expansion
Revenue
$20.39M*
▲ 6.9% YoY
Gross margin
87.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Confident tone TearCare reimbursement and MAC coverage Surgical Glaucoma / OMNI growth 2025 guidance raise
Revenue
$19.91M
▼ 1.2% YoY
Diluted EPS
$-0.16
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript
Revenue
$19.56M
▼ 8.5% YoY
Diluted EPS
$-0.23
Gross margin
84.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript
Positive tone Omni surgical glaucoma performance TearCare reimbursement progress Dry eye segment growth
Revenue
$17.51M
▼ 9.1% YoY
Diluted EPS
$-0.28
Gross margin
86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-14
Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Call Transcript
Cautious tone Surgical Glaucoma (OMNI) Performance and Strategy TearCare Reimbursement and Dry Eye Progress MIGS Market Headwinds and LCD Restrictions
Revenue
$19.07M*
▲ 1.7% YoY
Gross margin
86.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript
Cautious tone Surgical Glaucoma / MIGS Market Recovery TearCare / Dry Eye Franchise and Payer Access OMNI Product and Clinical Profile
Revenue
$20.16M
▲ 0.7% YoY
Diluted EPS
$-0.22
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript
Confident tone Dry Eye / TearCare Commercialization and Coverage SAHARA Clinical Data and Health Economics TearCare Price Increase and Adoption
Revenue
$21.37M
▼ 9% YoY
Diluted EPS
$-0.25
Gross margin
85.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript
Positive tone Surgical Glaucoma growth and recovery Dry Eye / TearCare business Sales force and commercial scaling
Revenue
$19.27M
▲ 2.3% YoY
Diluted EPS
$-0.33
Gross margin
85.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript
Positive tone Surgical Glaucoma / OMNI Performance LCD Reimbursement Uncertainty 2024 Guidance & Growth Outlook
Revenue
$18.75M*
▼ 8.7% YoY
Gross margin
85.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript
Revenue
$20.01M
▲ 7.1% YoY
Diluted EPS
$-0.27
Gross margin
86.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Sight Sciences, Inc. (SGHT) Q2 2023 Earnings Call Transcript
Revenue
$23.47M
▲ 36.2% YoY
Diluted EPS
$-0.30
Gross margin
85.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Sight Sciences, Inc. (SGHT) Q1 2023 Earnings Call Transcript
Revenue
$18.82M
▲ 26.5% YoY
Diluted EPS
$-0.35
Gross margin
83.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Sight Sciences, Inc. (SGHT) Q4 2022 Earnings Call Transcript
Revenue
$20.54M*
▲ 39.9% YoY
Gross margin
82.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Sight Sciences, Inc. (SGHT) Q3 2022 Earnings Call Transcript
Revenue
$18.68M
▲ 42.6% YoY
Diluted EPS
$-0.46
Gross margin
84.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Sight Sciences, Inc. (SGHT) Q2 2022 Earnings Call Transcript
Revenue
$17.23M
▲ 37.4% YoY
Diluted EPS
$-0.50
Gross margin
84.1%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Sight Sciences, Inc. (SGHT) Q1 2022 Earnings Call Transcript
Revenue
$14.88M
▲ 72.3% YoY
Diluted EPS
$-0.49
Gross margin
79.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-24
Sight Sciences, Inc. (SGHT) Q4 2021 Earnings Call Transcript
Revenue
$14.69M*
Gross margin
86.8%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Sight Sciences, Inc. (SGHT) Q3 2021 Earnings Call Transcript
Revenue
$13.10M
▲ 51.4% YoY
Diluted EPS
$-0.43
Gross margin
84.3%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Sight Sciences, Inc. (SGHT) Q2 2021 Earnings Call Transcript
Revenue
$12.54M
▲ 257.9% YoY
Gross margin
81.6%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts CIK 1531177 CUSIP 82657M105 13F (30d) 4 filings 4 filers Visit website Investor relations